1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with sodium taurodeoxycholate in 2 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (sodium taurodeoxycholate) | Trials (sodium taurodeoxycholate) | Recent Studies (post-2010) (sodium taurodeoxycholate) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 448 | 3 | 68 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, R; Deng, X; Ihse, I; Soltesz, V; Sun, Z; Wang, X | 1 |
| Andersson, E; Andersson, R; Börjesson, A; Leveau, P; Sun, Z; Wang, X | 1 |
2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and sodium taurodeoxycholate
| Article | Year |
|---|---|
Effect of a platelet-activating factor antagonist on pancreatitis-associated gut barrier dysfunction in rats.
Topics: Acute Disease; Animals; Bacterial Translocation; Calcium; Capillary Permeability; Endothelium, Vascular; Enterobacteriaceae; Hematocrit; Imidazoles; Intestinal Mucosa; Leucine; Lipase; Male; Pancreas; Pancreatitis; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Taurodeoxycholic Acid | 1998 |
Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant.
Topics: Acute Disease; Animals; Capillary Permeability; Chromium Radioisotopes; Endothelium, Vascular; Humans; Imidazoles; Interleukin-1; Interleukin-6; Intestinal Mucosa; Intestine, Small; Iodine Radioisotopes; Leucine; Leukocytes; Male; Pancreatitis; Peroxidase; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Serum Albumin; Taurodeoxycholic Acid | 2005 |